RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.

BACKGROUND Tyrosine kinase inhibitors (TKIs) are the cornerstone of successful clinical management of patients with chronic myeloid leukemia (CML). Quantitative monitoring of the percentage of the fusion transcript BCR-ABL1 (breakpoint cluster region-c-abl oncogene 1, non-receptor tyrosine kinase) BCR-ABL1IS (%BCR-ABL1IS) by reverse transcription-quantitative PCR (RT-qPCR) is the gold standard strategy for evaluating patient response to TKIs and classification into prognostic subgroups. However, this approach can be challenging to perform in a reproducible manner. Reverse-transcription digital PCR (RT-dPCR) is an adaptation of this method that could provide the robust and standardized workflow needed for truly standardized patient stratification. METHODS BCR-ABL1 and ABL1 transcript copy numbers were quantified in a total of 102 samples; 70 CML patients undergoing TKI therapy and 32 non-CML individuals. 3 commercially available digital PCR platforms (QS3D, QX200 and Raindrop) were compared with the platform routinely used in the clinic for RT-qPCR using the EAC (Europe Against Cancer) assay. RESULTS Measurements on all instruments correlated well when the %BCR-ABL1IS was ≥0.1%. In patients with residual disease below this level, greater variations were measured both within and between instruments limiting comparable performance to a 4 log dynamic range. CONCLUSIONS RT-dPCR was able to quantify low-level BCR-ABL1 transcript copies but was unable to improve sensitivity below the level of detection achieved by RT-qPCR. However, RT-dPCR was able to perform these sensitive measurements without use of a calibration curve. Adaptions to the protocol to increase the amount of RNA measured are likely to be necessary to improve the analytical sensitivity of BCR-ABL testing on a dPCR platform.

[1]  Ramesh Ramakrishnan,et al.  Taking qPCR to a higher level: Analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution. , 2010, Methods.

[2]  Christopher M. Hindson,et al.  Absolute quantification by droplet digital PCR versus analog real-time PCR , 2013, Nature Methods.

[3]  Stephen R Quake,et al.  Correction: Digital PCR provides sensitive and absolute calibration for high throughput sequencing , 2008, BMC Genomics.

[4]  Katayoun Rezvani,et al.  Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Jim F Huggett,et al.  Evaluation of digital PCR for absolute DNA quantification. , 2011, Analytical chemistry.

[6]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[7]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[8]  N. Cross.  Standardisation of molecular monitoring for chronic myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.

[9]  Alexandra S. Whale,et al.  Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation , 2012, Nucleic acids research.

[10]  C. Foy,et al.  Evaluation of Digital PCR for Absolute RNA Quantification , 2013, PloS one.

[11]  J. Apperley.  Chronic myeloid leukaemia , 2015, The Lancet.

[12]  H. Einsele,et al.  Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) , 2012, Leukemia.

[13]  P. Corbisier,et al.  Absolute quantification of genetically modified MON810 maize (Zea mays L.) by digital polymerase chain reaction , 2010, Analytical and bioanalytical chemistry.

[14]  H Emons,et al.  A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR , 2014, Leukemia.

[15]  Tania Nolan,et al.  The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments. , 2013, Clinical chemistry.

[16]  F. Watzinger,et al.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program , 2003, Leukemia.

[17]  N. Cross,et al.  Fast‐mode duplex qPCR for BCR‐ABL1 molecular monitoring: Innovation, automation, and harmonization , 2012, American journal of hematology.

[18]  Blaza Toman,et al.  Standard reference material 2366 for measurement of human cytomegalovirus DNA. , 2013, The Journal of molecular diagnostics : JMD.

[19]  Martin C. Müller,et al.  Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[21]  Letizia Foroni,et al.  Technical aspects and clinical applications of measuring BCR‐ABL1 transcripts number in chronic myeloid leukemia , 2009, American journal of hematology.

[22]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[23]  N. Cross,et al.  Guidelines for the measurement of BCR‐ABL1 transcripts in chronic myeloid leukaemia , 2011, British journal of haematology.

[24]  Jim F Huggett,et al.  Considerations for digital PCR as an accurate molecular diagnostic tool. , 2015, Clinical chemistry.

[25]  David Bryder,et al.  Transcription factor profiling in individual hematopoietic progenitors by digital RT-PCR , 2006, Proceedings of the National Academy of Sciences.

[26]  D. Colomer,et al.  Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia , 2015, Leukemia.

[27]  H. Kantarjian,et al.  Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data , 2012 .